title: Effect of ulcerative colitis treatment on transforming growth factor beta(1) in plasma and rectal mucosa.
abstract: The aim of this study was to evaluate the effect of active ulcerative colitis (UC) treatment on transforming growth factor beta(1) (TGF-beta(1)) concentration in plasma and rectal mucosa measured in 28 patients. The highest plasma values were observed in patients with the severe course of the disease (74.2+/-14.0 ng/ml), and they were significantly higher than in the group with mild one (43.7+/-5.6 ng/ml). Mean TGF-beta(1) measured in mucosal samples from patients with severe UC (563+/-146 pg/mg protein) doubled values from patients with mild UC (286+/-65 pg/mg protein). Plasma and mucosal TGF-beta(1) correlated significantly with disease activity index (DAI) and clinical activity index (CAI). Plasma TGF-beta(1) correlated additionally with scored endoscopic degree of mucosal injury. Treatment caused significant decrease of plasma and mucosal TGF-beta(1) concentrations. Patients who responded completely had higher baseline plasma and mucosal TGF-beta(1) that decreased significantly after the treatment. These results show that plasma and mucosal concentrations of transforming growth factor beta(1) are strongly associated with ulcerative colitis activity, and successful treatment of the disease results with decrease of their levels. More effective response to the treatment can be achieved in patients with higher baseline concentrations of TGF-beta(1).
authors.affiliation: Department of Infectious Diseases, Intestinal Diseases Unit, Medical Academy of Białystok, 15-540, Zurawia str., 14, Białystok, Poland. alicja@priv.onet.pl
authors.forename: Alicja
authors.initials: A
authors.lastname: Wiercińska-Drapało
authors.forename: Robert
authors.initials: R
authors.lastname: Flisiak
authors.forename: Danuta
authors.initials: D
authors.lastname: Prokopowicz
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003093:Colitis, Ulcerative / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000737:chemistry* / Q000187:drug effects / Q000473:pathology; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D012007:Rectum / Q000737:chemistry* / Q000187:drug effects / Q000473:pathology; D012720:Severity of Illness Index; D012460:Sulfasalazine / Q000008:administration & dosage / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000097:blood*; D053773:Transforming Growth Factor beta1
chemical_list: C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D012460:Sulfasalazine; D019804:Mesalamine; D011241:Prednisone